INTERCEPT PHARMACEUTICALS, INC.
ICPT evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- oca (Phase 3)
What it means
What to watch
Prepared research question
What matters most for ICPT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
oca (Phase 3)
Next Catalyst
—
Tracking 3 pipeline candidates · 5 clinical trials for INTERCEPT PHARMACEUTICALS, INC..
Similar companies
Run INTERCEPT PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INTERCEPT PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is INTERCEPT PHARMACEUTICALS, INC.'s lead drug candidate?
INTERCEPT PHARMACEUTICALS, INC.'s most advanced tracked candidate is oca (Phase 3) for Primary Biliary Cholangitis; Biliary Atresia.
Who is the CEO of INTERCEPT PHARMACEUTICALS, INC.?
Madison Avenue is the chief executive officer of INTERCEPT PHARMACEUTICALS, INC. (ICPT).
What therapeutic areas does INTERCEPT PHARMACEUTICALS, INC. focus on?
INTERCEPT PHARMACEUTICALS, INC. develops therapies across Oncology, Infectious Disease, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.